Business
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal CareSAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced it has entered into an agreement with the Gates Foundation under which it will receive up to approximately $4
About this update from Dare Bioscience, Inc.
[{"type":"image","alt":"Daré Bioscience, Inc.","displaySize":"","headline":null,"caption":"Daré Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":226,"url":"https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ch5vpzW1QsXLUt._W_BLpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd","width":300,"height":226}},"lazy":false},{"type":"text","content":"Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care","length":162,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced it has entered into an agreement with the Gates Foundation under which it will receive up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for third-party research projects addressing preeclampsia, one of the most serious and underserved complications of pregnancy.","length":559,"tagName":"p"},{"type":"text","content":"Through this engagement, Daré will provide strategic mentorship, technical guidance, and tailored project management support to Grand Challenges grantee organizations in various geographies worldwide whose pre-clinical research projects are focused on the prevention, diagnosis, and treatment of preeclampsia. Despite its devastating impact—preeclampsia is a leading cause of maternal and infant illness and death globally—there are currently no FDA-approved treatments for this life-threatening condition.","length":506,"tagName":"p"},{"type":"text","content":"“Preeclampsia remains one of the greatest unmet needs in women’s health, with approximately 76,000 moms and 500,000 babies worldwide losing their lives to this condition each year,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “This engagement by the foundation will allow us not only to contribute our expertise to advance the work of global innovators, but also to gain invaluable insights into scientific and ...